Financial Information
This section of the Co-Diagnostics InvestorRoom houses up to date financial reporting information and interactive tools to provide you with the resources you need to manipulate and understand our current financial standing.
Please note: All data in this section is provided by a 3rd party provider and may be delayed up to 20 minutes. Co-Diagnosticsassumes no responsibility for the accuracy of this data and provides it for informational purposes only.
| Beta | (1.98) |
|---|---|
| Shares Outstanding | 28.7M |
| Average Volume (10 days) | 733.0K |
| Qtrly Dividend (Ann. Yield) | -- (--) |
Analyst Views
| Current Mean Recommendation | Buy |
|---|
| Strong Buy | 1 | |
|---|---|---|
| Buy | 0 | |
| Hold | 1 | |
| Underperform | 0 | |
| Sell | 0 |
Recent Insider Transactions
Dwight H Egan Director, Chief Executive Officer | (11,954) Dispose Jan 15, 2021 |
|---|---|
Dwight H Egan Director, Chief Executive Officer | (38,046) Sell Jan 15, 2021 |
Richard S. Serbin Director | (10,000) Sell Jan 14, 2021 |
James Nelson Director | (11,900) Sell Jan 13, 2021 |
James Nelson Director | (600) Sell Jan 13, 2021 |
Co-Diagnostics is a molecular diagnostics company with a unique mathematical approach to DNA test design. Our products offer a unique value proposition, making the detection of infectious disease and genetic disorders far more affordable worldwide.
Co-Diagnostics, Inc.
2401 South Foothill Dr, Suite D
Salt Lake City, Utah 84109
United States
1 (801) 438-1036
© 2016-2020 Co-Diagnostics, Inc. • All Rights Reserved.
COMPANY
LATEST NEWS RELEASE
Co-Diagnostics is a molecular diagnostics company with a unique mathematical approach to DNA test design. Our products offer a unique value proposition, making the detection of infectious disease and genetic disorders far more affordable worldwide.
Co-Diagnostics, Inc.
2401 South Foothill Dr, Suite D
Salt Lake City, Utah 84109
United States
1 (801) 438-1036
COMPANY
© 2016-2020 Co-Diagnostics, Inc. • All Rights Reserved.